OWC Pharmaceutical Research Corp. - Quarter Report: 2016 September (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 10-Q
___________________
ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2016
Commission file number 0-54856
OWC PHARMACEUTICAL RESEARCH CORP.
(Exact Name Of Registrant
As Specified In Its Charter)
Delaware | 98-0573566 |
(State of Incorporation) | (I.R.S. Employer Identification No.) |
22 Shaham Steet, P.O. Box 8324, Petach Tikva, Israel | 4918103 |
(Address of Principal Executive Offices) | (ZIP Code) |
Registrant's Telephone Number, Including Area Code: +972 (0) 3-758-2657
Indicate by check
mark whether the registrant (1) has filed all reports required to be filed by Section 13
or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act) or a smaller reporting company .
Large accelerated filer ¨ | Accelerated filer ¨ | Non-Accelerated filer ¨ | Smaller reporting company x |
On November 14, 2016, the Registrant had 135,305,474 shares of common stock issued and outstanding.
Item |
Description |
Page |
|||
---|---|---|---|---|---|
PART I - FINANCIAL INFORMATION |
|||||
ITEM 1. | FINANCIAL STATEMENTS | 3 | |||
Consolidated Balance Sheets | 3 | ||||
Consolidated Statements of Operations | 4 | ||||
Consolidated Statements of Comprehensive Loss | 5 | ||||
Consolidated Statements of Cash Flows | 6 | ||||
Notes to Unaudited Interim Consolidated Financial Statements | 7 | ||||
ITEM 2. | MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS. | 13 | |||
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. | 18 | |||
ITEM 4. | CONTROLS AND PROCEDURES. | 18 | |||
PART II - OTHER INFORMATION |
|||||
ITEM 1. | LEGAL PROCEEDINGS. | 18 | |||
ITEM 1A. | RISK FACTORS. | 19 | |||
ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. | 19 | |||
ITEM 3. | DEFAULT UPON SENIOR SECURITIES. | 19 | |||
ITEM 4. | MINE SAFETY DISCLOSURE. | 19 | |||
ITEM 5. | OTHER INFORMATION. | 19 | |||
ITEM 6. | EXHIBITS. | 19 |
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS Back to Table of Contents
OWC Pharmaceutical Research Corp. | ||||
Consolidated Balance Sheets | ||||
At September 30, 2016 (Unaudited) and December 31, 2016 | ||||
Back to Table of Contents | ||||
September 30, 2016 | ||||
(Unaudited) | December 31, 2015 | |||
ASSETS | ||||
Current assets: | ||||
Cash | $ | 90,327 | $ | 357,161 |
Other receivables | 12,218 | 11,797 | ||
Prepaid expenses | 9,716 | 38,591 | ||
Total current assets | 112,261 | 407,549 | ||
Property and equipment, net | 17,504 | 22,899 | ||
Total Assets | $ | 129,765 | $ | 430,448 |
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||
Current liabilities: | ||||
Accounts payable - trade | $ | 8,866 | $ | 28,125 |
Accrued expenses | 25,821 | 24,607 | ||
Customer deposit | 150,000 | 50,000 | ||
Advances and accounts payable to related parties | 1,820 | 1,820 | ||
Convertible notes payable, net of discount | - | 3,074 | ||
Total current liabilities | 186,507 | 107,626 | ||
Non-current liabilities | ||||
Notes payable | 50,000 | - | ||
Total non-current liabilities | 50,000 | 107,626 | ||
Total liabilities | 236,507 | 107,626 | ||
Stockholders' equity (deficit): | ||||
Preferred stock, $0.00001 par value; 20,000,000 shares authorized; no shares issued and outstanding | - | - | ||
Common stock, $0.00001 par value; 500,000,000 shares authorized; and | ||||
121,416,585 and 81,460,875 issued and outstanding at September 30, 2016 and December 31, 2015, respectively | 1,216 | 815 | ||
Additional paid in capital | 8,708,358 | 8,533,525 | ||
Common stock subscription receivable | (651,730) | (651,730) | ||
Common stock subscription payable | 12,500 | - | ||
Accumulated deficit | (8,177,778) | (7,548,866) | ||
Accumulated other comprehensive income | 692 | (10,922) | ||
Total stockholders' equity | (106,742) | 322,822 | ||
Total Liabilities and Stockholders' equity (deficit) | $ | 129,765 | $ | 430,448 |
See notes to unaudited interim consolidated financial statements. |
OWC Pharmaceutical Research Corp. | ||||||||
Consolidated Statements of Operations | ||||||||
For the Three and Nine-Month Periods Ended September 30, 2016 and 2015 | ||||||||
(Unaudited) | ||||||||
Back to Table of Contents | ||||||||
For the three |
For the three | For the nine | For the nine | |||||
Months ended | Months ended | Months ended | Months ended | |||||
September 30, 2016 | September 30, 2015 | September 30, 2016 | September 30, 2015 | |||||
Revenues |
$ |
- |
$ |
- |
$ |
- |
$ |
- |
Expenses | ||||||||
General and administrative | 74,898 |
311,391 |
380,920 |
1,135,481 |
||||
Research and development | 30,363 |
96,834 |
102,182 |
286,774 |
||||
(Loss) from operations | (105,261) | (408,225) | (483,102) | (1,422,255) | ||||
Other income (expense) | ||||||||
Loss on settlement of debt | (4,521) | - | (4,521) | - | ||||
Interest expense | (2,055) | - | (43,615) | - | ||||
Change in fair value of derivative liabilities | (2,426) | - | (14,024) | - | ||||
Amortization of debt discount | (26,531) | - | (83,650) | - | ||||
Total other income (expense) | (35,533) |
- |
(145,810) | - | ||||
Total costs and expenses | (140,794) | (408,225) | (628,912) | (1,422,255) | ||||
Net loss before income taxes | (140,794) | (408,225) | (628,912) | (1,422,255) | ||||
Income tax | - |
- |
- |
- |
||||
Net loss | $ |
(140,794) | $ |
(408,225) | $ |
(628,912) | $ |
(1,422,255) |
Basic and diluted per share amounts: | ||||||||
Basic and diluted net loss | $ |
(0.00) |
$ |
(0.00) |
$ |
(0.01) |
$ | (0.02) |
Weighted average shares outstanding | ||||||||
(basic and diluted) | 85,204,293 |
81,219,430 |
$ |
82,717,789 |
$ | 80,308,561 |
||
See notes to unaudited interim consolidated financial statements. |
OWC Pharmaceutical Research Corp. | ||||||||
Consolidated Statements Comprehensive Loss | ||||||||
For the Three and Nine Months Ended September 30, 2016 and 2015 | ||||||||
(Unaudited) | ||||||||
Back to Table of Contents | ||||||||
For the three | For the three | For the nine | For the nine | |||||
months ended | months ended | months ended | months ended | |||||
September 30, 2016 | September 30, 2015 | September 30, 2016 | September 30, 2015 | |||||
Net loss | $ | (140,794) | $ | (408,225) | $ | (628,912) | $ | (1,422,255) |
Other comprehensive income (loss), net of tax: | ||||||||
Foreign currency translation adjustments | 3,933 | 893 | 11,614 | (4,715) | ||||
Total other comprehensive income (loss), net of tax | 3,933 | 893 | 11,614 | (4,715) | ||||
Comprehensive loss | $ | (136,861) | $ | (407,332) | $ | (617,298) | $ | (1,426,970) |
See notes to unaudited interim consolidated financial statements. |
OWC Pharmaceutical Research Corp. | ||||
For the Nine-Month Periods Ended September 30, 2016 and 2015 |
||||
(Unaudited) |
||||
For the Nine | For the Nine | |||
Months ended | Months ended | |||
September 30, 2016 | September 30, 2015 | |||
Cash flows from operating activities: | ||||
Net loss | $ |
(628,912) |
$ |
(1,422,255) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||
Derivative valuation adjustments | 14,024 | - | ||
Loss on settlement of debt | 4,521 | - | ||
Amortization of debt discount | 83,650 | - | ||
Depreciation expense | 7,255 | 6,960 | ||
Common stock issued for services | - | 360,369 | ||
Warrants issued for services | 8,074 | 10,839 | ||
Changes in net assets and liabilities: | ||||
(Increase) decrease in accounts receivable | (421) | - | ||
(Increase) decrease in accounts receivable - related party | - | 13,346 | ||
(Increase) decrease in prepaid expenses | 29,454 | - | ||
Increase (decrease) accounts payable - related party | (1,820) | (138) | ||
Increase (decrease) in accounts payable | (19,258) | 28,020 | ||
Increase (decrease) in customer deposits | 100,000 | - | ||
Increase (decrease) in accrued expenses | 5,595 |
(40,693) |
||
Cash used in operating activities | (397,838) |
(1,043,552) |
||
Cash flow from investing activities: | ||||
Purchase of equipment | (1,860) | (3,179) | ||
Cash used in investing activities | (1,860) |
(3,179) |
||
Cash flow from financing activities: | ||||
Proceeds from issuance of common stock | - | 114,000 | ||
Proceeds of debt borrowings | 50,000 | - | ||
Proceeds of debt borrowings - convertible | 78,500 | - | ||
Payment of financing costs | (7,250) | - | ||
Cash provided by financing activities | 121,250 |
114,000 |
||
Foreign currency translation | 11,614 |
(4,715) |
||
Change in cash | (266,834) |
(937,446) |
||
Cash - beginning of period | 357,161 |
1,469,267 |
||
Cash - end of period | $ |
90,327 |
$ |
531,821 |
Supplement cash flow information: | ||||
Non-cash transactions: | ||||
Debt discount arising from derivatives | $ | 41,974 | $ | - |
Conversion of debt | $ | 175,138 | $ | - |
OWC Pharmaceutical Research Corp. 1. The Company and Significant Accounting Policies Organizational Background: OWC Pharmaceutical Research Corp. ("OWCP" or the "Company") is a Delaware
corporation and was incorporated under the laws of the State of Delaware on
March 7, 2008. We are a medical cannabis research and development company
that applies conventional pharmaceutical research protocols and disciplines
to the field of medical cannabis with the objective of establishing a
leadership position in the research and development of medical cannabis
therapies, products and delivery technologies. We are currently engaged in
the research and development of cannabis-based medical products (the
"Product Prospects") for the treatment of multiple myeloma, psoriasis and
fibromyalgia as well as development of a cannabis soluble tablet delivery
system that may have applications for other indications. We also provide
consulting services to governmental and private entities to assist them with
developing and implementing tailor-made comprehensive medical cannabis
programs. OWC Pharmaceutical Research Corp. ("OWCP"
or the "Company") is a Delaware corporation and was incorporated under the
laws of the State of Delaware on March 7, 2008. The Company is engaged in
two distinct business activities: (i) work with GUMI to commercialize and
market the Company's Electromagnetic Percussion Device (the "Device"); and
(ii) research and development of Cannabis-based medical products for the
treatment of a variety of medical conditions and/or diseases such as
multiple myeloma, psoriasis, PTSD, migraines and a unique delivery system. The accompanying financial statements of OWCP were prepared from the
accounts of the Company under the accrual basis of accounting. Certain
amounts in the financial statements have been reclassified to conform to the
current presentation. The reclassifications had no effect on the reported
net loss. Basis of Presentation: The accompanying financial statements
have been prepared in conformity with accounting principles generally
accepted in the United States of America, which contemplate continuation of
the Company as a going concern. The Company has not established any source
of revenue to cover its operating costs, and as such, has incurred an
operating loss since inception. These and other factors raise substantial
doubt about the Company's ability to continue as a going concern. The
accompanying financial statements do not include any adjustments to reflect
the possible future effects on the recoverability and classification of
assets or the amounts and classification of liabilities that may result from
the possible inability of the Company to continue as a going concern. Principles of Consolidation: The financial statements include
the accounts of OWC Pharmaceutical Research Corp. and its wholly owned
subsidiary One World Cannabis, Inc. (OWC). All significant inter-company
balances and transactions have been eliminated. Significant Accounting Policies Use of Estimates: The preparation of financial statements in
conformity with generally accepted accounting principles requires management
to make estimates and assumptions that affect reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date
of the financial statement and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from the estimates. Cash and Cash Equivalents: For financial statement presentation
purposes, the Company considers those short-term, highly liquid investments
with original maturities of three months or less to be cash or cash
equivalents. There were no cash equivalents at September 30, 2016 and
December 31, 2015. Property and Equipment: New property and equipment are recorded
at cost. Property and equipment included in the bankruptcy proceedings and
transferred to the Trustee had been valued at liquidation value.
Depreciation is computed using the straight-line method over the estimated
useful lives of the assets, generally 5 years. Expenditures for renewals and
betterments are capitalized. Expenditures for minor items, repairs and
maintenance are charged to operations as incurred. Gain or loss upon sale or
retirement due to obsolescence is reflected in the operating results in the
period the event takes place. Valuation of Long-Lived Assets: We review the recoverability of
our long-lived assets including equipment, goodwill and other intangible
assets, when events or changes in circumstances occur that indicate that the
carrying value of the asset may not be recoverable. The assessment of
possible impairment is based on our ability to recover the carrying value of
the asset from the expected future pre-tax cash flows (undiscounted and
without interest charges) of the related operations. If these cash flows are
less than the carrying value of such asset, an impairment loss is recognized
for the difference between estimated fair value and carrying value. Our
primary measure of fair value is based on discounted cash flows. The
measurement of impairment requires management to make estimates of these
cash flows related to long-lived assets, as well as other fair value
determinations. Foreign Currency: Non-U.S. entity operations are recorded in the
functional currency of each entity. Results of operations for non-U.S.
dollar functional currency entities are translated into U.S. dollars using
average currency rates. Assets and liabilities are translated using currency
rates at period end. Foreign currency translation adjustments are recorded
as a component of other comprehensive income (loss) within stockholders'
equity. Stock Based Compensation: Stock-based awards are accounted for
using the fair value method in accordance with ASC 718, Share-Based
Payments. Our primary type of share-based compensation consists of stock
options. We use the Black-Scholes option pricing model in valuing options.
The inputs for the valuation analysis of the options include the market
value of the Company's common stock, the estimated volatility of the
Company's common stock, the exercise price of the warrants and the risk free
interest rate. Accounting For Obligations And Instruments Potentially To Be Settled
In The Company's Own Stock: We account for obligations and
instruments potentially to be settled in the Company's stock in accordance
with FASB ASC 815, Accounting for Derivative Financial Instruments. This
issue addresses the initial balance sheet classification and measurement of
contracts that are indexed to, and potentially settled in, the Company's own
stock. Fair Value of Financial Instruments: FASB ASC 825, "Financial
Instruments," requires entities to disclose the fair value of financial
instruments, both assets and liabilities recognized and not recognized on
the balance sheet, for which it is practicable to estimate fair value. FASB
ASC 825 defines fair value of a financial instrument as the amount at which
the instrument could be exchanged in a current transaction between willing
parties. At September 30, 2016 and December 31, 2015, the carrying value of
certain financial instruments (cash and cash equivalents, accounts payable
and accrued expenses.) approximates fair value due to the short-term nature
of the instruments or interest rates, which are comparable with current
rates. Fair Value Measurements: The Company measures fair value under
a framework that utilizes a fair value hierarchy that prioritizes the inputs
to valuation techniques used to measure fair value. The hierarchy gives the
highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (level 1 measurements) and the lowest priority to
unobservable inputs (level 3 measurements). The three levels of inputs which
prioritize the inputs used in measuring fair value are: Level 1: Inputs to the valuation methodology are unadjusted quoted
prices for identical assets or liabilities in active markets that the
Company has the ability to access. Level 2: Inputs to the
valuation methodology include: If the asset or liability has a specified
(contractual) term, the level 2 input must be observable for substantially
the full term of the asset or liability. The assets or liability's fair value measurement level within the fair
value hierarchy is based on the lowest level of any input that is
significant to the fair value measurement. Valuation techniques used need to
maximize the use of observable inputs and minimize the use of unobservable
inputs. The following table presents assets that were measured and recognize
at fair value on September 30, 2016 and December 31, 2015 and the year then
ended on a recurring basis: Fair Value Measurements at September 30, 2016 Quoted Prices in Active Significant Other Significant Markets for Identical Assets Observable Inputs Unobservable Inputs Total (Level 1) (Level 2) (Level 3) $ - $ $ - $ - $ - $ $ - $ - Fair Value Measurements at December 31, 2015 Quoted Prices in Active Significant Other Significant Markets for Identical Assets Observable Inputs Unobservable Inputs Total (Level 1) (Level 2) (Level 3) $ - $ $ - $ - $ - $ $ - $ - When the Company changes its valuation inputs for measuring financial
assets and liabilities at fair value, either due to changes in current
market conditions or other factors, it may need to transfer those assets or
liabilities to another level in the hierarchy based on the new inputs used.
The Company recognizes these transfers at the end of the reporting period
that the transfers occur. For the fiscal periods ended September 30, 2016
and December 31, 2015, there were no significant transfers of financial
assets or financial liabilities between the hierarchy levels. Earnings per Common Share: We compute net income (loss) per
share in accordance with ASC 260, Earning per Share. ASC 260 requires
presentation of both basic and diluted earnings per share (EPS) on the face
of the income statement. Basic EPS is computed by dividing net income (loss)
available to common shareholders (numerator) by the weighted average number
of shares outstanding (denominator) during the period. Diluted EPS gives
effect to all dilutive potential common shares outstanding during the period
using the treasury stock method and convertible preferred stock using the
if-converted method. In computing Diluted EPS, the average stock price for
the period is used in determining the number of shares assumed to be
purchased from the exercise of stock options or warrants. Diluted EPS
excludes all dilutive potential shares if their effect is anti-dilutive. Income Taxes: We have adopted ASC 740, Accounting for Income
Taxes. Pursuant to ASC 740, we are required to compute tax asset benefits
for net operating losses carried forward. The potential benefits of net
operating losses have not been recognized in these financial statements
because the Company cannot be assured it is more likely than not it will
utilize the net operating losses carried forward in future years. We must make certain estimates and judgments in determining income tax
expense for financial statement purposes. These estimates and judgments
occur in the calculation of certain tax assets and liabilities, which arise
from differences in the timing of recognition of revenue and expense for tax
and financial statement purposes. Deferred tax assets and liabilities are determined based on the
differences between financial reporting and the tax basis of assets and
liabilities using the tax rates and laws in effect when the differences are
expected to reverse. ASC 740 provides for the recognition of deferred tax
assets if realization of such assets is more likely than not to occur.
Realization of our net deferred tax assets is dependent upon our generating
sufficient taxable income in future years in appropriate tax jurisdictions
to realize benefit from the reversal of temporary differences and from net
operating loss, or NOL, carryforwards. We have determined it more likely
than not that these timing differences will not materialize and have
provided a valuation allowance against substantially all of our net deferred
tax asset. Management will continue to evaluate the realizability of the deferred
tax asset and its related valuation allowance. If our assessment of the
deferred tax assets or the corresponding valuation allowance were to change,
we would record the related adjustment to income during the period in which
we make the determination. Our tax rate may also vary based on our results
and the mix of income or loss in domestic and foreign tax jurisdictions in
which we operate. In addition, the calculation of our tax liabilities involves dealing with
uncertainties in the application of complex tax regulations. We recognize
liabilities for anticipated tax audit issues in the U.S. and other tax
jurisdictions based on our estimate of whether, and to the extent to which,
additional taxes will be due. If we ultimately determine that payment of
these amounts is unnecessary, we will reverse the liability and recognize a
tax benefit during the period in which we determine that the liability is no
longer necessary. We will record an additional charge in our provision for
taxes in the period in which we determine that the recorded tax liability is
less than we expect the ultimate assessment to be. ASC 740 which requires recognition of estimated income taxes payable or
refundable on income tax returns for the current year and for the estimated
future tax effect attributable to temporary differences and carry-forwards.
Measurement of deferred income tax is based on enacted tax laws including
tax rates, with the measurement of deferred income tax assets being reduced
by available tax benefits not expected to be realized. Uncertain Tax Positions: When tax returns are filed, it is
highly certain that some positions taken would be sustained upon examination
by the taxing authorities, while others are subject to uncertainty about the
merits of the position taken or the amount of the position that would be
ultimately sustained. In accordance with the guidance of FASB ASC 740-10,
Accounting for Uncertain Income Tax Positions, the benefit of a tax position
is recognized in the financial statements in the period during which, based
on all available evidence, management believes it is more likely than not
that the position will be sustained upon examination, including the
resolution of appeals or litigation processes, if any. Tax positions taken
are not offset or aggregated with other positions. Tax positions that meet
the more-likely-than-not recognition threshold are measured as the largest
amount of tax benefit that is more than 50 percent likely of being realized
upon settlement with the applicable taxing authority. The portion of the
benefits associated with tax positions taken that exceeds the amount
measured as described above should be reflected as a liability for
unrecognized tax benefits in the accompanying consolidated balance sheets
along with any associated interest and penalties that would be payable to
the taxing authorities upon examination. Our federal and state income tax returns are open for fiscal years ending
on or after December 31, 2010. We are not under examination by any
jurisdiction for any tax year. At September 30, 2016, we had no material
unrecognized tax benefits and no adjustments to liabilities or operations
were required under FASB ASC 740-10. Recent Accounting Pronouncements Share-Based Payments: In March 2016, amended guidance was issued for employee share-based
payment awards. The amended guidance makes several modifications related to
the accounting for forfeitures, employer tax withholding on share-based
compensation and excess tax benefits or deficiencies. The amended guidance
also clarifies the statement of cash flows presentation for share-based
awards. The amended guidance is effective for us prospectively commencing in
the first quarter of 2018. Early adoption is permitted. Deferred Income Taxes: In November 2015, amended guidance was issued for the balance sheet
classification of deferred income taxes. The amended guidance requires the
classification of all deferred tax assets and liabilities as noncurrent on
the balance sheet instead of separating deferred taxes into current and
noncurrent amounts. Early adoption is permitted. In April 2015, the Financial Accounting Standards Board ("FASB") issued
Accounting Standards Update ("ASU") 2015-03, "Interest-Imputation of
Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
Costs." ASU 2015-03 requires that debt issuance costs related to a
recognized debt liability be presented in the balance sheet as a direct
deduction from the carrying amount of that debt liability, consistent with
debt discounts. Currently, debt issuance costs are recognized as deferred
charges and recorded as other assets. The guidance is effective for annual
and interim periods beginning after December 15, 2015 with early adoption
permitted and is to be implemented retrospectively. Adoption of the new
guidance will only affect the presentation of the Company's consolidated
balance sheets and will have no impact to our financial statements. Management does not anticipate that the adoption of these standards will
have a material impact on the financial statements. The preparation of these financial statements in conformity with
accounting principles generally accepted in the United States requires us to
make estimates and judgments that affect the reported amounts of assets,
liabilities, revenues and expenses, and related disclosure of contingent
assets and liabilities. On an on-going basis, we evaluate our estimates,
including those related intangible assets, income taxes, insurance
obligations and contingencies and litigation. We base our estimates on
historical experience and on various other assumptions that are believed to
be reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities
that are not readily apparent from other resources. Actual results may
differ from these estimates under different assumptions or conditions. The Financial Statements presented herein have been prepared by us in
accordance with the accounting policies described in our December 31, 2015
Annual Report and should be read in conjunction with the Notes to Financial
Statements which appear in that report. In the opinion of management, the information furnished in these interim
financial statements reflects all adjustments necessary for a fair statement
of the financial position and results of operations and cash flows as of and
for the three and nine-month periods ended September 30, 2016 and 2015. All
such adjustments are of a normal recurring nature. The Financial Statements
do not include some information and notes necessary to conform to annual
reporting requirements. 2. Stockholders' Equity Common Stock issued in 2016 Shares Issued upon Conversion of Debt: In September 2016, the Company agreed
to the conversion of $116,000 in
principal and $3,140 in interest due on two convertible notes of
which resulted into the issuance of 39,955,710 and 13,888,889 shares which
are subject to stock payable with a value of $12,500 resulting in a loss of
$4,521. Options Issued for Services: During the three months ended March 31, 2016 we issued 200,000 common
stock options. The options valued at $8,074 were granted for services
provided by unrelated parties. The fair value of the options was estimated
at the date of grant using the Black-Sholes-Merton pricing model. The
Black-Sholes-Merton pricing model assumptions used are as follows: expected
dividend yield of 0%; risk-free interest rate of 1.11%; expected volatility
of 196%, and option term of 2.75 years. Common Stock issued in 2015 Stock Issued for Cash: In August of 2015, we also received $24,000 through a placement of
100,000 common stock units. Those units were sold at $0.24 per unit. Each
unit consisted of two shares of common stock and two warrants to purchase
common stock. 100,000 warrants are exercisable at $0.12 and expire on August
31, 2016 while the other 100,000 warrants are exercisable at $0.25 and
expire on August 31, 2017. In February of 2015 we sold 800,000 shares to one investor for the
offering price of $0.05 per share that resulted in total proceeds of
$40,000. During 2015, we also received $50,000 through a placement of common
stock units. Those units were sold at $0.15 per unit. Each unit consisted of
one share of common stock and one warrant to purchase common stock. The
related warrants are exercisable at $0.25 and expire on December 31, 2016. Stock Issued for Services: During the interim period ended September 30, 2015 we issued 1,614,935
shares of our common stock to unrelated parties as payment for services. The
shares were valued at the closing price as of the date of the agreements
(ranging from $0.19 to $0.25) and resulted in full recognition of $360,369
in consulting services expense. During the period ended June 30, 2015, the
Company cancelled 500,000 shares of common stock previously issued for
services. Warrants Granted As part of the 2015 unit offering, the Company issued a total of 333,333
warrants to purchase up to 333,333 shares of common stock at $0.25 per
share. The relative fair value of the warrants attached to the common stock
issued was estimated at the date of grant using the Black-Sholes-Merton
pricing model. The relative fair value of the attached to the common stock
component is $26,416 and the relative fair value of the warrants is $23,584
as of the grant date. In February, 2015 we issued 64,935 warrants for services. The warrants
are exercisable at $0.25 and expire February 23, 2016. We used the
Black-Scholes-Merton pricing model and inputs described below to estimate
the fair value of $10,839. The Black-Sholes-Merton pricing model assumptions used are as follows:
expected dividend yield of 0%; risk-free interest rate of 0.10%-.0.11%;
expected volatility of 242%, and warrant exercise period based upon the
stated terms. 3. Related Party Transactions Due Related Parties: Amounts due related parties totaled $1,820 at
September 30, 2016 and $1,820 at December 31, 2015, respectively. The
Company paid $16,163 during the period ended September 30, 2016 and $21,943 in
2015 in rent to a related party. 4. Notes Payable Unsecured Notes Payable Without Conversion Rights A loan agreement for up to $300,000 was issued September 28, 2016. The
agreement allows for six incremental draws of $50,000 to be drawn monthly
beginning September 1, 2016 in order to meet future working capital demands.
The loan advances are non-interest bearing. The loan is may be repaid at any
time but matures 36 months from the date of issue. As of September 30th,
2016 the company has drawn down $50,000 leaving an available balance of
$250,000. Unsecured Notes Payable With Conversion Rights A convertible note for $78,500 issued on February 2, 2016, bears interest
at 8.0% per annum until paid or converted and matures November 2, 2016. Any
or all of the outstanding balance of the note may be converted at the option
of the holder at any time into common stock of the company at a variable
conversion price of 65% of market price. Upon the issuance of the
convertible note, the Company bifurcated the embedded conversion feature and
recorded an initial derivative liability of $41,974 (the estimated fair
market value at the date of grant based on the Binomial option pricing
model) all of which was allocated as debt discount. During 2015 the Company agreed to provide unsecured promissory notes with
an unrelated party for $37,500. The note is non-interest bearing and is due
on September 16, 2016. The note has not been paid and is in default at
September 30, 2016. The note has a future conversion right that allows the
holder to convert the principal balance into the Company's common stock at
the lender's sole discretion at 50% of the then market price per share. In
accordance with ASC 470, the Company has analyzed the beneficial nature of
the conversion terms and determined that a beneficial conversion feature (BCF)
exists because the effective conversion price was less than the quoted
market price at the time of the issuance. The Company calculated the value
of the BCF using the intrinsic method as stipulated in ASC 470. The BCF of
$37,500 had been recorded as a discount to the notes payable and to
Additional Paid-in Capital. For the nine months September 30, 2016, the Company has amortized $83,650 ($0
in 2015) of the discount arising from the embedded derivative and beneficial
conversion feature of the two outstanding notes. During August and September 2016, in accordance with the original terms
of the notes, at the option of the note holders, the entire combined balance
of $116,000 and interest of $3,140 was converted into
39,955,710 and 13,888,889 shares which
are subject to stock payable with a value of $12,500 resulting in a loss of
$4,521. At the date of conversions, the entire derivative liability
associated with the bifurcated conversion feature of was marked-to-market,
resulting in an increase of $2,426, to a total derivative liability of
$55,998 which was reclassified to paid in capital on the date of conversion.
The $2,426 change was recorded as a derivative valuation charge in the
Consolidated Statement of Operations. In September, 2016 the Company
authorized the issuance of 53,844,599 shares of common stock upon the
conversion of $116,000 in principal and $3,140 in interest due on two
convertible notes of which 39,955,710 were issued and 13,888,889 shares are
subject to stock payable with a value of $12,500 resulting in a loss of
$4,521 . 5. Derivative Liabilities Embedded Conversion Feature To properly account for the convertible notes payable discussed in Note
4, the Company performed a detailed analysis to obtain a thorough
understanding of the transaction. The Company reviewed FASB ASC 815, to
identify whether any equity-linked features in the notes are freestanding or
embedded. The notes were then analyzed in accordance with FASB ASC 815 to
determine if the anti-dilution feature should be bifurcated and accounted
for at fair value and remeasured at fair value in income. The Company
determined that the anti-dilution feature met the requirements for
bifurcation pursuant to FASB ASC 815 due to the variable conversion price
and therefore accounted for the anti-dilution features of the notes as a
derivative liability. Changes in fair value of the derivative financial
instruments are recognized in the Company's statement of operations as a
derivative valuation gain or loss. The conversion of $55,998 during the three months ended September 30, 2016 resulted in a
charge of $14,024
and an adjustment charge to the market of $2,426 for the three months ended
September 30, 2016. The Company values its simple conversion option derivatives using the a
lattice model. Assumptions used include: - life through the note maturity date During August and September 2016, in accordance with the original terms
of the notes, at the option of the note holders, the entire balance of
$78,500 and interest of $3,140 was converted into 20,142,568 shares of
common stock. At the date of conversions, the entire derivative liability
associated with the bifurcated conversion feature of was marked-to-market,
resulting in an increase of $2,496, to a total derivative liability of
$55,998 which was reclassified to paid in capital on the date of conversion.
The $2,426 change was recorded as a derivative valuation charge in the
Consolidated Statement of Operations 6. Going Concern The accompanying financial statements have been prepared in conformity
with accounting principles generally accepted in the United States of
America, which contemplate continuation of the Company as a going concern.
The Company has not established any source of revenue to cover its operating
costs, and as such, has incurred an operating loss since inception. Further,
as of September 30, 2016, the cash resources of the Company were
insufficient to meet its current business plan. These and other factors
raise substantial doubt about the Company's ability to continue as a going
concern. The accompanying financial statements do not include any
adjustments to reflect the possible future effects on the recoverability and
classification of asset or the amounts and classification of liabilities
that may result from the possible inability of the Company to continue as a
going concern. 7. Subsequent Events There were no subsequent events following the period ended September 30,
2016 and throughout the date of the filing of Form 10-Q. ITEM
2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATION Back to Table of Contents The following discussion contains forward-looking statements.
Forward-looking statements give our current expectations or forecasts of future events.
You can identify these statements by the fact that they do not relate strictly to
historical or current facts. They use of words such as "anticipate",
"estimate", "expect", "project", "intend",
"plan", "believe", and other words and terms of similar meaning in
connection with any discussion of future operating or financial performance. From time to
time, we also may provide forward-looking statements in other materials we release to the
public. Plan of Operations We
are engaged in
research
and development of cannabis-based medical products for the treatment of
a variety of medical conditions such as multiple
myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD)
and migraine, and (ii)
consulting services to companies and governmental agencies with respect to complex international medical cannabis protocols and
regulations.
We
have not yet commenced any significant activities related to our consulting services. Our
goal is to become a leader in the research and development of cannabis-based medical drugs and treatments. To achieve our goal,
we plan to focus our activities on the following areas:
Research
and Development Our
research
and development is focused primarily on exploring several formulations
containing active compounds from the cannabis
plant, including (but not exclusive to) the cannabinoids CBD and THC,
and identifying potential therapeutic applications of the
synergistic effects of these active compounds. The synergistic
contributions of our formulations have not yet been scientifically
researched and demonstrated. We aim to standardize the formulations
across the extracts as a whole, not simply by reference to
their key active components (CBD and/or THC). Although
there are existing reports and studies on CBD and THC, our formulations will contain several active compounds from the cannabis
plant, that must be fully researched and documented in order to verify its effectiveness to indications, at what doses and which
method of administration will be the most appropriate and effective. One
World
Cannabis plans to produce pharmaceutical-grade cannabinoid-based
products and treatments, that will be standardized in composition,
formulation and dose, administered by means of an appropriate and
efficient delivery system, and tested in properly controlled
pre-clinical and clinical studies. OWC plans to conduct its researche,
led by internationally renowned investigators, at the facilities
of leading Israeli hospitals and scientific institutions. The Company
will adhere to legislation, rules and guidelines regarding
the investigations. Dr. Baruch, OWC's Director of Research and
Regulatory Affairs, and Alon Sinai, OWC's Chief Operating
Officer, will monitor the investigations and researches. To
date,
OWC has signed three research collaboration and license agreements with
Sheba Academic Medical Center, Tel Hashomer, Israel
("Sheba"). Sheba is a university-affiliated hospital that serves as
Israel's national medical center and the
most comprehensive medical center in the Middle East. Within the
framework of the agreements with Sheba, OWC will initiate three
studies at the Sheba facilities to explore the effect of three
formulations, all based on active ingredients in the cannabis extracts,
on multiple myeloma, psoriasis and fibromyalgia (a specific formulation
to each indication). In
addition,
OWC signed an R&D service agreement with G.C. Group Ltd., an Israeli
pharmaceutical R&D company, in April 2015,
to provide formulation development services for OWC's new delivery
system in the form of a cannabis soluble tablet. The
cannabis soluble tablet could provide physicians with the ability to
control and administrate optimal dosage, to replace the most
common usage/delivery method of medical cannabis today, which is not
acceptable by scientists and physicians, such as smoking,
edibles and oil extracts with no adequate means of dosage control. The
agreement was terminated on December 31, 2015. The
Company
expects to start developing other delivery systems, designed for
different indications, during 2016. The
Company
has recently signed a Memorandum of Understanding (MoU) with Emilia
Cosmetics Ltd., a large Israeli private label manufacturer,
for the development, manufacture and marketing of a cannabinoid-based
topical cream to treat psoriasis. The Company will initiate
the development of the topical cream by the end of the first quarter of
2016, at Emilia Cosmetics labs located in Yerucham, Israel.
After the completion of the formulation development, expected to be
during the second quarter of 2016, the Company will initiate
a phase I study at the Sheba facilities to explore the effect of topical
cream on psoriasis. However, we do not know if our expectations
will be fulfilled in a timely manner, if at all, or that the costs of
development will exceed our anticipation. To
date,
One World Cannabis has filed eight provisional patents with the United
States Patent and Regulatory Office (USPTO), all
related to its line of activity related to cannabis-based medical
products. Assuming the successful completion of the clinical
trials, of which there can be no assurance, the Company believes that it
will be able to retain the intellectual rights and secure
patent protections. While
we
retain full ownership on our intellectual property rights that we
conceived prior to the signing of the research collaboration
and license agreements with Sheba Academic Medical Center, the psoriasis
and fibromyalgia agreements with Sheba provide that all
intellectual property rights that is conceived during the course of the
research is to be jointly owned by Sheba and One World
Cannabis. Pursuant
to
the collaboration agreements, we expect to pay Sheba $330,000 for
conducting the multiple myeloma trial between the 3rd quarter
of 2015 and the second quarter of 2016. In addition, we expect to
commence pre-clinical studies on fibromyalgia and psoriasis
during the second quarter of 2016. Pursuant to the collaboration
agreements, we are obliged to pay Sheba $300,000 throughout 2016
for conducting the psoriasis research, and $100,000 for the fibromyalgia
research during the two years of the study. We currently
have the financial resources to fund our obligations under these
agreements, but anticipate that we will require additional funding
during the next 12 months for our continuing and planned expanded
operations.
Research
and Development Status The
following table summarizes the stages of development for each of our current Product Prospects.
OWC's
Investigation on Multiple Myeloma Dr.
Merav
Leiba, Head of Multiple Myeloma Outpatient Clinic and Multiple Myeloma
Research Lab at Sheba's Hematology Institute,
led the in vitro tests on multiple myeloma. Dr. Leiba, a specialist in
Internal Medicine and Hematology, was a postdoctoral fellow
at the Jerome Lipper Multiple Myeloma Center at Dana Farber Cancer
Institute, Boston, Massachusetts (2006-2008). Dr. Leiba has
participated in numerous clinical and investigational studies aimed at
developing novel drugs for multiple myeloma. Our
in
vitro tests results on multiple myeloma cells studied outside their
normal biological context, on which we announced on June
17, 2015, led us to proceed with further pre-clinical study (safety and
toxicity, PK, PD) of our formulation, to find out whether
it has scientific merit for further development as an investigational
new drug. While we are encouraged by the results of the
limited in vitro tests, there can be no assurance that any clinical
trial will result in commercially viable products or treatments. Clinical
trials
are expensive, time consuming and difficult to design and implement.
We, as well as the regulatory authorities in Israel
and elsewhere, such as an IRB (Helsinki committee), IMCU - Israel
Medical Cannabis Unit, or the FDA, may suspend, delay or terminate
our clinical trials at any time, may require us, for various reasons, to
conduct additional clinical trials, or may require a
particular clinical trial to continue for a longer duration than
originally planned, including, among others: ● lack
of effectiveness of any formulation or delivery system during clinical trials; ●
discovery of serious or unexpected toxicities or side effects experienced by trial participants or other safety issues; ●
slower than expected rates of subject recruitment and enrollment rates in clinical trials; ● delays
or inability in manufacturing or obtaining sufficient quantities of materials for use in clinical trials due to regulatory and
manufacturing constraints; ●
delays in obtaining regulatory authorization to commence a trial, including IRB approvals, licenses required for obtaining and
using cannabis for research, either before or after a trial is commenced; ●
unfavorable results from ongoing pre-clinical studies and clinical trials. ●
patients or investigators failing to comply with study protocols; ● patients
failing to return for post-treatment follow-up at the expected rate; ● sites
participating in an ongoing clinical study withdraw, requiring us to engage new sites; ● third-party
clinical
investigators decline to participate in our clinical studies, do not
perform the clinical studies on the anticipated
schedule, or act in ways inconsistent with the established investigator
agreement, clinical study protocol, good clinical practices,
and other Institutional Review Board requirements; ●
third-party entities do not perform data collection and analysis in a timely or accurate manner or at all; ● regulatory
inspections of our clinical studies require us to undertake corrective action or suspend or terminate our clinical studies; Any
of the foregoing could have a material adverse effect on our business, results of operations and financial condition. Consulting
Services OWCP
believes
that the complexity of the medical cannabis programs has created a
demand for consulting and advisory services in different
aspects of the medical cannabis industry. The Company's services are
designed to help government officials, policy-makers
and regulatory agencies develop and implement tailor-made comprehensive
medical cannabis programs. In addition, One World Cannabis
offers medical cannabis regulatory compliance services and patient-care
consultancy services. Our
initial activities to secure consulting contracts will be in member states of the European Union and states of the United States
that allow for public medical cannabis programs. OWC
management has the expertise in designing training programs for physicians, caregivers, and researches that are essential to the
establishment of a successful, patient-focused medical cannabis program. By working with policy-makers, government officials,
public agencies, and privately owned businesses, we believe we can also raise the public's awareness of the benefits of
cannabis-based treatments and products.
In
furtherance
of our plans, we may, in the future, consider strategic acquisitions
and joint ventures as well as other projects
to grow our business activities including but not limited to: product
licensing and royalty agreements, consulting, and strategic
alliances to support our Product Prospect development. However, there
can be no assurance that this strategy will be successful
in generating any revenues or growing out business.
Notes to Unaudited Interim
Consolidated Financial Statements
September 30, 2016
Back to
Table of Contents
- Quoted prices for similar assets or
liabilities in active markets;
- Quoted prices for identical or similar
assets or liabilities in inactive markets;
- Inputs other than quoted
prices that are observable for the asset or liability;
- Inputs that are
derived principally from or corroborated by observable market data by
correlation or other means.
Level 3: Inputs to the
valuation methodology are unobservable and significant to the fair value
measurement.
None
-
Total
assets and liabilities at fair value
-
None
-
Total
assets and liabilities at fair value
-
- expected volatility-152%,
-
expected dividends-none
- exercise prices as set forth in the
agreements,
- common stock price of the underlying share on the
valuation date, and
- number of shares to be issued if the instrument is
converted
Target
Indication
Collaborator
Status
Multiple
Myeloma
Sheba
●
Entered
into a research agreement for in vitro studies
Academic
●
Negotiating
terms of a research agreement for in vivo studies
Medical
Center
●
Completed
one in vitro study
●
Proceeding
with further pre-clinical in vitro studies (safety and toxicity, pharmacokinetic, and pharmacodynamic)
●
Submitted
a clinical trial protocol to the Israeli Institutional Review Board and received its approval to commence a clinical study
●
Intend
to commence a clinical study in the first quarter of 2016
●
Drafted
a clinical trial protocol synopsis, which we believe will assist us
in preparing an application for orphan status designation
●
Entered
into a Research Collaboration and License Agreement but have not commenced any studies to date
Psoriasis
Sheba
Academic
Medical Center
●
Drafted
a protocol of a Phase I, double blind, randomized, placebo
controlled, multiple escalating dose study to determine the safety,
tolerability and pharmacokinetic profile of medical grade cannabis
in healthy volunteers
●
Entered
into a nonbinding memorandum of understanding for the development, manufacture and marketing of a cannabinoid-based topical
cream
Psoriasis
Emilia
Cosmetics Ltd.
●
Intend
to enter into a binding agreement in the second quarter of 2016
●
Intend
to initiate development of the topical cream in the second quarter of 2016
●
Entered
into a research agreement for in vitro studies \
Fibromyalgia
Sheba
Academic Medical Center
●
Drafted
a clinical trial protocol synopsis, which we believe will assist us
in preparing an application for orphan status designation
New
delivery system - cannabis soluble tablet
G.C.
Group
Ltd.
●
Completed
a proof of concept (the R=Research phase) of the desired end product (the soluble tablet) to test the fabric, durability,
solidification and other features of the cannabis soluble tablet.
Results of Operations during the three months ended September 30, 2016 as compared to the three months ended September 30, 2015
We have not generated any revenue during the three months ended September 30, 2016 and 2015. We have operating expenses related to general and administrative expenses and research and development. During the three months ended September 30, 2016, we incurred a net loss of $140,794 due to general and administrative expenses of $74,898, research and development expenses of $30,363, a loss of $4,521 related to a debt settlement, interest expense of $2,055, a valuation loss on derivatives of $2,426 and expenses due to amortization of debt discount of $26,531 as compared to a net loss of $408,225 due to general and administrative expenses of $311,391 and research and development expenses of $96,834.
Our general and administrative expenses decreased by $236,493 during the three months ended September 30, 2016 as compared to the same period in the prior year. This decrease of 76% is primarily the result of decreased stock-based compensation. The charge relating to stock-based compensation expense was $0 for the three months ended September 30, 2016, compared to $119,199 for the three months ended September 30, 2015.
Our research and development expenses decreased to $30,363 during the three months ended September 30, 2016, compared to $96,834 during the same period in the prior year. The decrease by $66,471 or 69% was primarily due to decreased payments related to our collaboration agreements.
Results of Operations during the nine months ended September 30, 2016 as compared to the nine months ended September 30, 2015
We have not generated any revenue during the nine months ended September 30, 2016 and 2015. We have operating expenses related to general and administrative expenses and research and development. During the nine months ended September 30, 2016, we incurred a net loss of $628,912 due to general and administrative expenses of $380,920, research and development expenses of $102,182, a loss of $4,521 related to a debt settlement, interest expense of $43,615, a valuation loss on derivatives of $14,024 and expenses due to amortization of debt discount of $83,650 as compared to a net loss of $1,422,255 due to general and administrative expenses of $1,135,481 and research and development expenses of $286,774.
Our general and administrative expenses decreased by $754,561 during the nine months ended September 30, 2016 as compared to the same period in the prior year. This decrease of 66% is primarily the result of decreased stock-based compensation. The charge relating to stock-based compensation expense was $0 for the nine months ended September 30, 2016, compared to $360,369 for the nine months ended September 30, 2015.
Our research and development expenses decreased to $102,182 during the nine months ended September 30, 2016, compared to $286,774 during the same period in the prior year. The decrease by $184,592 or 64% was primarily due to decreased payments related to our collaboration agreements.
Liquidity and Capital Resources
On September 30, 2016, we had current assets of $112,261 consisting of $90,327 in cash, other receivables of $12,218 and prepaid expenses of $9,716. We had property and equipment, net of accumulated depreciation of $19,118 valued at $17,504 as of September 30, 2016. We had total assets of $129,765 as of September 30, 2016.
On December 31, 2015, we had current assets of $407,549 consisting of $357,161 in cash, other receivables of $11,797 and prepaid assets of $38,591. We had property and equipment, net of accumulated depreciation of $11,863, valued at $22,899 as of December 31, 2015. We had total assets of $430,448 as of December 31, 2015.
On September 30, 2016, we had $186,507 in current liabilities consisting of $8,866 in accounts payable, $25,281 in accrued expenses, customer deposits of $150,000 and $1,820 in advances and accounts payable to related parties.
On December 31, 2015, we had $107,626 in current liabilities consisting of $28,125 in accounts payable, $24,607 in accrued expenses, customer deposits of $50,000, $1,820 in advances and accounts payable to related parties and convertible notes payable of $3,074.
We had negative working capital of $74,246 at September 30, 2016 as compared to positive working capital of $299,923 on December 31, 2015. Our accumulated deficit as of September 30, 2016 and December 31, 2015 were $8,177,778 and $7,548,866, respectively.
We used $397,838 in our operating activities during the nine month ended September 30, 2016, which was due to a net loss of $628,912 offset by derivative valuations adjustments of $14,024, a loss of $4,521 related to debt settlements, amortization of debt discount expense of $83,650, depreciation expense of $7,255, warrant expenses valued at $8,074, a decrease in accounts receivable of $421, a decrease in prepaid expenses of $29,454, an increase in accounts payable to related party of $1,820, an increase in accounts payable of $19,258, an increase in customer deposits of $100,000 and an increase in accrued expenses of $5,595.
We used $1,043,552 in our operating activities during the nine months ended September 30, 2015, which was due to a net loss of $1,422,255 offset by depreciation expenses of $6,960, shares issued for services valued at $360,369, warrants issued for services valued at $10,839, a decrease in accounts receivable of $13,346, a decrease in accounts payable to a related party of $138, an increase in accounts payable of $28,020 and an increase in accrued expenses of $40,693.
We used $1,860 and $3,179 during the nine months ended September 30, 2016 and 2015, respectively, to purchase property and equipment.
Our financing activities during the nine months ended September 30, 2016 provided us with $121,250 from debt borrowings of $128,500 offset buy $7,250 in debt issuance cost. We financed our negative cash flow from operations during the nine months ended September 30, 2015 through proceeds from issuance of common stock of $90,000.
Based upon our cash position of $90,327 at September 30, 2016, we believe that we need to raise additional capital, either equity or debt during the remainder of fiscal year 2016 in order to fund our plan of operations including our research and development initiatives for the next twelve months. There can be no assurance, however, that additional capital will be sufficient to fund our currently anticipated expenditure requirements for the next twelve-month period nor can there be any assurance that financing will be available at satisfactory terms and conditions or at all, for that matter.
Our auditors have issued an opinion on our financial statements which includes a statement describing our going concern status. This means that there is substantial doubt that we can continue as an on-going business for the next twelve months unless we obtain additional capital to pay our bills and meet our other financial obligations. This is because we have not generated any revenues and no revenues are anticipated until we begin marketing the product. Accordingly, we must raise capital from sources other than the actual sale of the product. We must raise capital to implement our project and stay in business. Even if we raise the maximum amount of money in this offering, we do not know how long the money will last, however, we do believe it will last at least twelve months.
Our lack of operating history may make it difficult to raise capital. Our inability to borrow funds or raise equity capital to facilitate our business plan may have a material adverse effect on our financial condition and future prospects.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Back to Table of Contents
None.
ITEM 4. CONTROLS AND PROCEDURES Back to Table of Contents
Evaluation of disclosure controls and procedures.
As of September 30, 2016, the Company's chief executive officer and chief financial officer conducted an evaluation regarding the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act. Based upon the evaluation of these controls and procedures as provided under the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013), our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were ineffective as September 30, 2016. Management has identified corrective actions to address the weaknesses and plans to implement them during the fourth quarter of 2016.
Changes in Internal Control Over Financial Reporting
There were no changes in the Company's internal control over financial reporting during the period covered by this report, which were identified in connection with management's evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS Back to Table of Contents
We are not currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us. However, from time to time, we may become a party to certain legal proceedings in the ordinary course of business.
ITEM 1A. RISK FACTORS Back to Table of Contents
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1. Description of Business, subheading "Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2015, which could materially affect our business, financial condition or future results.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Back to Table of Contents
During the three-months ended September 30, 2016, the Company issued 2,307,692 restricted shares of common stock valued at $300,000 to Michepro Holding Ltd. in reliance upon the exemptions provided in Section 4(2) of the Securities Act of 1933, as amended (the "Act") and Regulation D and Regulation S promulgated by the United States Securities and Exchange Commission (the "SEC") under the Act.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES Back to Table of Contents
None.
ITEM 4. MINE SAFETY DISCLOSURE. Back to Table of Contents
Not applicable.
ITEM 5. OTHER INFORMATION Back to Table of Contents
Not applicable.
ITEM 6. EXHIBITS Back to Table of Contents
(a) The following documents are filed as exhibits to this report on Form 10-Q or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.
Exhibit No. |
Description |
---|---|
31.1 | Section 302 Certification of the Sarbanes-Oxley Act of 2002 of the Company's CEO, Mordechi Bignitz, filed herewith. |
31.2 | Section 302 Certification of the Sarbanes-Oxley Act of 2002 of the Company's CFO, Shmuel De-Saban, filed herewith. |
32.1 | Section 906 of the Sarbanes-Oxley Act of 2002 of Mordechi Bignitz as CEO, filed herewith |
32.2 | Section 906 of the Sarbanes-Oxley Act of 2002 of Shmuel De-Saban as CFO, filed herewith |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.
Signature | Title | Date |
/s/ Mordechai Bignitz | Chief Executive Officer (Principal Executive Officer) | November 14, 2016 |
Mordechai Bignitz | ||
/s/ Shmuel De-Saban | Chief Financial Officer (Principal Financial and Accounting Officer) | November 14, 2016 |
Shmuel De-Saban | ||
Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature | Title | Date |
/s/ Mordechai Bignitz | Chief Executive Officer | November 14, 2016 |
Mordechai Bignitz | ||
/s/ Mordechai Bignitz | Chairman | November 14, 2016 |
Mordechai Bignitz | ||